What is a stock summary page? Click here for an overview.
Business Description
BioXcel Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US09075P1057
Description
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.29 | |||||
| Equity-to-Asset | -2.43 | |||||
| Debt-to-Equity | -1.11 | |||||
| Debt-to-EBITDA | -2.33 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -27 | |||||
| Beneish M-Score | -1.94 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 35.4 | |||||
| 3-Year EPS without NRI Growth Rate | 29.7 | |||||
| 3-Year FCF Growth Rate | 17.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 35.05 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 179.25 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.24 | |||||
| 9-Day RSI | 43.72 | |||||
| 14-Day RSI | 41.02 | |||||
| 3-1 Month Momentum % | -69.9 | |||||
| 6-1 Month Momentum % | -69.27 | |||||
| 12-1 Month Momentum % | -93.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.68 | |||||
| Quick Ratio | 1.65 | |||||
| Cash Ratio | 1.34 | |||||
| Days Inventory | 317.13 | |||||
| Days Sales Outstanding | 44.94 | |||||
| Days Payable | 2553.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21 | |||||
| Shareholder Yield % | -497.98 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 5.38 | |||||
| Operating Margin % | -2859.84 | |||||
| Net Margin % | -2630.14 | |||||
| FCF Margin % | -3169.34 | |||||
| ROA % | -96.54 | |||||
| ROIC % | -2782.24 | |||||
| 3-Year ROIIC % | -761.19 | |||||
| ROC (Joel Greenblatt) % | -3815.2 | |||||
| ROCE % | -127.16 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.72 | |||||
| EV-to-EBIT | -1.84 | |||||
| EV-to-Forward-EBIT | -0.8 | |||||
| EV-to-EBITDA | -1.86 | |||||
| EV-to-Forward-EBITDA | -1.24 | |||||
| EV-to-Revenue | 36.23 | |||||
| EV-to-Forward-Revenue | 32.57 | |||||
| EV-to-FCF | -1.14 | |||||
| Earnings Yield (Greenblatt) % | -54.27 | |||||
| FCF Yield % | -837 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioXcel Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2.104 | ||
| EPS (TTM) (€) | -23.949 | ||
| Beta | 0.65 | ||
| 3-Year Sharpe Ratio | -0.95 | ||
| 3-Year Sortino Ratio | -1.13 | ||
| Volatility % | 63.61 | ||
| 14-Day RSI | 41.02 | ||
| 14-Day ATR (€) | 0.043662 | ||
| 20-Day SMA (€) | 2.56 | ||
| 12-1 Month Momentum % | -93.34 | ||
| 52-Week Range (€) | 0.16 - 44.8 | ||
| Shares Outstanding (Mil) | 5.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioXcel Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioXcel Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
BioXcel Therapeutics Inc Frequently Asked Questions
What is BioXcel Therapeutics Inc(FRA:BX20)'s stock price today?
The current price of FRA:BX20 is €2.56. The 52 week high of FRA:BX20 is €44.80 and 52 week low is €0.16.
When is next earnings date of BioXcel Therapeutics Inc(FRA:BX20)?
The next earnings date of BioXcel Therapeutics Inc(FRA:BX20) is 2025-05-09 Est..
Does BioXcel Therapeutics Inc(FRA:BX20) pay dividends? If so, how much?
BioXcel Therapeutics Inc(FRA:BX20) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers